0001387131-23-011903.txt : 20231004 0001387131-23-011903.hdr.sgml : 20231004 20231004070527 ACCESSION NUMBER: 0001387131-23-011903 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20231004 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231004 DATE AS OF CHANGE: 20231004 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Tonix Pharmaceuticals Holding Corp. CENTRAL INDEX KEY: 0001430306 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 261434750 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36019 FILM NUMBER: 231306563 BUSINESS ADDRESS: STREET 1: 26 MAIN STREET, SUITE 101 CITY: CHATHAM STATE: NJ ZIP: 07928 BUSINESS PHONE: 212-980-9155 MAIL ADDRESS: STREET 1: 26 MAIN STREET, SUITE 101 CITY: CHATHAM STATE: NJ ZIP: 07928 FORMER COMPANY: FORMER CONFORMED NAME: TAMANDARE EXPLORATIONS INC. DATE OF NAME CHANGE: 20080320 8-K 1 tnxp-8k_100423.htm CURRENT REPORT
0001430306 false 0001430306 2023-10-04 2023-10-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of report (date of earliest event reported): October 4, 2023

 

TONIX PHARMACEUTICALS HOLDING CORP.  

(Exact name of registrant as specified in its charter)

 

Nevada 001-36019 26-1434750

(State or Other Jurisdiction  

of Incorporation)  

(Commission  

File Number) 

(IRS Employer  

Identification No.)  

 

26 Main Street, Chatham, New Jersey 07928

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (862) 904-8182

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)  

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock TNXP The NASDAQ Capital Market

   

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). 

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

 

 

 

 

 
 

 

 

Item 7.01 Regulation FD Disclosure.

 

On October 4, 2023, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced that that the European Patent Office (“EPO”) issued European Patent No. 3242676 (the “Patent”) to the Company on October 4, 2023. A copy of the press release which discusses this matter is furnished hereto as Exhibit 99.01, and incorporated herein by reference.

 

The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.01 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the United States Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the United States Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 8.01Other Events.

 

On October 4, 2023, the Company announced that the EPO issued the Patent to the Company on October 4, 2023. The Patent, entitled “Magnesium-Containing Oxytocin Formulations and Methods of Use”, claims methods and compositions for treating pain, including migraine headaches, using intranasal magnesium-containing oxytocin formulations. This Patent, excluding possible patent term extensions, is expected to provide the Company with market exclusivity in the member states of the European Patent Office until 2036.

 

Forward- Looking Statements 

 

This Current Report on Form 8-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

 

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the SEC. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. 

 

Item 9.01 Financial Statements and Exhibits.

 

(d)  

Exhibit

No.

   Description.
   

99.01

104

  

Press release of the Company, dated October 4, 2023

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 
 

 

SIGNATURE

 

Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  TONIX PHARMACEUTICALS HOLDING CORP.
   
Date: October 4, 2023 By: /s/ Bradley Saenger  
  Bradley Saenger
  Chief Financial Officer

 

  

 

 EX-99.01 2 ex99-01.htm PRESS RELEASE OF THE COMPANY, DATED OCTOBER 4, 2023

 

Tonix Pharmaceuticals Holding Corp. 8-K

 

Exhibit 99.01

 

 

Tonix Pharmaceuticals Announces Issuance of EU Patent Covering Intranasal Potentiated Oxytocin (TNX-1900) for the Treatment of Pain

New patent expected to expire in 2036

Proof of concept data from Phase 2 study for prevention of migraine headache expected in early December 2023

CHATHAM, N.J., October 4, 2023 – Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that the European Patent Office (EPO) issued European Patent No. 3242676 to the Company on October 4, 2023. The patent, entitled “Magnesium-Containing Oxytocin Formulations and Methods of Use”, claims methods and compositions for treating pain, including migraine headaches, using intranasal magnesium-containing oxytocin formulations. This patent, excluding possible patent term extensions, is expected to provide Tonix with market exclusivity in the member states of the European Patent Office until 2036. The U.S. Patent and Trademark Office (USPTO) has previously issued U.S. Patents No. 9,629,894 and 11,389,473 which are expected to provide market exclusivity in the U.S. until 2036.

In August 2023, Tonix announced it completed enrollment in its proof-of-concept Phase 2 PREVENTION study of TNX-1900 (intranasal potentiated oxytocin) for the prevention of migraine headache in chronic migraineurs with a total of 88 patients enrolled. The Company expects topline results from this trial in early December 2023.

“We believe this European patent combined with the U.S. issuance provides a strong patent position for TNX-1900 as we move forward in clinical development for the treatment of chronic migraine,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “With a differentiated formulation including magnesium, which Tonix has shown to potentiate the action of oxytocin at oxytocin receptors in animal models, we believe TNX-1900 has the potential to help those chronic migraine sufferers by engaging and stimulating oxytocin receptors in the trigeminal ganglia. By expanding our patent coverage in Europe, we are ensuring the IP protection of this unique approach.”

In addition to Tonix’s patents that protect certain uses including treating migraine, Tonix has licensed patents from INSERM, the French national health and medical research institute, that claim methods of treating feeding disorders with onset during neonatal development, specifically Prader Willi syndrome and non-organic failure to thrive (NOFTT), using oxytocin (EP 2575853, US8853158 and US9125862) and licensed patents from University of Geneva that claim methods of treating insulin resistance using oxytocin (US9101569 and EP2571511).

About Migraine

 

Migraine is a neurological condition that manifests in throbbing headache, often on one side of the head, that lasts at least four hours. It can also be accompanied by nausea, vomiting, visual disturbances, and sensitivity to bright light, strong smells, and loud noises.1 Epidemiological studies indicate that globally, approximately 1.2 billion individuals suffer from migraines annually.2 In the U.S., approximately 39 million Americans suffer from migraines and among these individuals, approximately four million experience chronic migraines (15 or more headache days per month).2

 

 
 

 

About TNX-1900

 

TNX-1900 (intranasal potentiated oxytocin) is a proprietary formulation of oxytocin in development as a candidate for prophylaxis of chronic migraine and for the treatment of craniofacial pain, insulin resistance and related conditions. In 2020, TNX-1900 was acquired from Trigemina, Inc. who had licensed the technology underlying the composition and method from Stanford University. TNX-1900 is a drug-device combination product, based on an intranasal actuator device that delivers oxytocin into the nose. Oxytocin is a naturally occurring human hormone that acts as a neurotransmitter in the brain. Oxytocin has no recognized addiction potential. It has been observed that low oxytocin levels in the body can lead to an increase in migraine headache frequency, and that increased oxytocin levels can relieve migraine headaches. Certain other chronic pain conditions are also associated with decreased oxytocin levels. Migraine attacks are caused, in part, by the activity of pain-sensing trigeminal nerve cells which, when activated, release of the calcitonin gene-related peptide (CGRP) which binds to receptors on other nerve cells and starts a cascade of events that is believed to result in headache. Oxytocin, when delivered via the nasal route, concentrates in the trigeminal system3 resulting in binding of oxytocin to receptors on neurons in the trigeminal system, inhibiting transmission of pain signals and releasing of the CGRP.4 Blocking CGRP release is a distinct mechanism compared with CGRP antagonist and anti-CGRP antibody drugs, which block the binding of CGRP to its receptor. With TNX-1900, the addition of magnesium to the oxytocin formula enhances oxytocin receptor binding5, its effects on trigeminal neurons, and its craniofacial analgesic effects in animal models.7 Intranasal oxytocin has been shown to be well tolerated in several clinical trials in both adults and children.6 Targeted nasal delivery results in low systemic exposure and lower risk of non-nervous system, off-target effects, which could potentially occur with systemic CGRP antagonists such as anti-CGRP antibodies.8 For example, CGRP has roles in dilating blood vessels in response to ischemia, including in the heart. We believe nasally targeted delivery of oxytocin could translate into selective blockade of CGRP release in the trigeminal ganglion and not throughout the body, which could be a potential safety advantage over systemic CGRP inhibition. In addition, daily dosing is more quickly reversible, in contrast to monthly or quarterly dosing, as is the case with anti-CGRP antibodies, giving physicians and their patients greater control.

 

1.https://www.mayoclinic.org/diseases-conditions/migraine-headache/symptoms-causes/syc-20360201
2.Burch et al., Migraine: Epidemiology, Burden, and Comorbidity, Neurol Clin 37 (2019) 631–649.
3.Yeomans DC, et al. Transl Psychiatry. 2021. 11(1):388.
4.Tzabazis A, et al. Cephalalgia. 2016. 36(10):943-50.
5.Antoni FA and Chadio SE. Biochem J. 1989. 257(2):611-4.
6.Yeomans, DC et al. 2017. US patent US2017368095
7.Cai Q, et al., Psychiatry Clin Neurosci. 2018. Mar;72(3):140-151.
8.MaassenVanDenBrink A, et al. Trends Pharmacol Sci. 2016. 37(9):779-788

 

 
 

 

Tonix Pharmaceuticals Holding Corp.*

 

Tonix is a biopharmaceutical company focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease and alleviate suffering. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg under a transition services agreement with Upsher-Smith Laboratories, LLC from whom the products were acquired on June 30, 2023. Zembrace SymTouch and Tosymra are each indicated for the treatment of acute migraine with or without aura in adults. Tonix’s development portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates. Tonix’s CNS development portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead development CNS candidate, TNX-102 SL (cyclobenzaprine HCl sublingual tablet), is in mid-Phase 3 development for the management of fibromyalgia, having completed enrollment of a potentially confirmatory Phase 3 study in the third quarter of 2023, with topline data expected in late December 2023. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Enrollment in a Phase 2 proof-of-concept study has been completed, and topline results were reported in the third quarter of 2023. TNX-601 ER (tianeptine hemioxalate extended-release tablets) is a once-daily oral formulation being developed as a treatment for major depressive disorder (MDD), that completed enrollment in a Phase 2 proof-of-concept study in the third quarter of 2023, with topline results expected in early November of 2023. TNX-4300 (estianeptine) is a single isomer version of TNX-601, small molecule oral therapeutic in preclinical development to treat MDD, Alzheimer’s disease and Parkinson’s disease. Relative to tianeptine, estianeptine lacks activity on the µ-opioid receptor while maintaining activity in the rat Novel Object Recognition test in vivo and the ability to activate PPAR-β/δ and neuroplasticity in tissue culture. TNX-1900 (intranasal potentiated oxytocin), is in development for preventing headaches in chronic migraine, and has completed enrollment in a Phase 2 proof-of-concept study with topline data expected in early December 2023. TNX-1900 is also being studied in binge eating disorder, pediatric obesity and social anxiety disorder by academic collaborators under investigator-initiated INDs. TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted Breakthrough Therapy designation by the FDA. A Phase 2 study of TNX-1300 is expected to be initiated in the fourth quarter of 2023. Tonix’s rare disease development portfolio includes TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome. TNX-2900 has been granted Orphan Drug designation by the FDA. Tonix’s immunology development portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. A Phase 1 study of TNX-1500 was initiated in the third quarter of 2023. Tonix’s infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases. The infectious disease development portfolio also includes TNX-3900 and TNX-4000, which are classes of broad-spectrum small molecule oral antivirals.

 

*Tonix’s product development candidates are investigational new drugs or biologics and have not been approved for any indication.

 

Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. Intravail is a registered trademark of Aegis Therapeutics, LLC, a wholly owned subsidiary of Neurelis, Inc. All other marks are property of their respective owners.

 

This press release and further information about Tonix can be found at www.tonixpharma.com.

 

 
 

 

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the Securities and Exchange Commission (the “SEC”) on March 13, 2023, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Investor Contact

Jessica Morris

Tonix Pharmaceuticals

investor.relations@tonixpharma.com

(862) 904-8182

 

Peter Vozzo

ICR Westwicke

peter.vozzo@westwicke.com

(443) 213-0505

 

Media Contact

Ben Shannon

ICR Westwicke

ben.shannon@westwicke.com

(919) 360-3039

 

 

 EX-101.SCH 3 tnxp-20231004.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 tnxp-20231004_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 tnxp-20231004_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Oct. 04, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 04, 2023
Entity File Number 001-36019
Entity Registrant Name TONIX PHARMACEUTICALS HOLDING CORP.
Entity Central Index Key 0001430306
Entity Tax Identification Number 26-1434750
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 26 Main Street
Entity Address, City or Town Chatham
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07928
City Area Code (862)
Local Phone Number 904-8182
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol TNXP
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 7 tnxp-8k_100423_htm.xml IDEA: XBRL DOCUMENT 0001430306 2023-10-04 2023-10-04 iso4217:USD shares iso4217:USD shares 0001430306 false 8-K 2023-10-04 TONIX PHARMACEUTICALS HOLDING CORP. NV 001-36019 26-1434750 26 Main Street Chatham NJ 07928 (862) 904-8182 false false false false Common Stock TNXP NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

JQ"(6,P$ "(" / M " 4X0 !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " "M M.$17)!Z;HJT #X 0 &@ @ &N$0 >&PO7W)E;',O=V]R M:V)O;VLN>&UL+G)E;'-02P$"% ,4 " "M.$1799!YDAD! #/ P $P M @ &3$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) + #X" #=$P ! end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://tonixpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tnxp-20231004.xsd tnxp-20231004_lab.xml tnxp-20231004_pre.xml tnxp-8k_100423.htm http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tnxp-8k_100423.htm": { "nsprefix": "TNXP", "nsuri": "http://tonixpharma.com/20231004", "dts": { "schema": { "local": [ "tnxp-20231004.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "tnxp-20231004_lab.xml" ] }, "presentationLink": { "local": [ "tnxp-20231004_pre.xml" ] }, "inline": { "local": [ "tnxp-8k_100423.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://tonixpharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-10-04", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tnxp-8k_100423.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-10-04", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tnxp-8k_100423.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001387131-23-011903-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001387131-23-011903-xbrl.zip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end